Home › NDC Lookup › Ingredients › Orphenadrine Citrate › 00641-6182-25
Orphenadrine citrate 60 mg/2mL Injection — NDC 00641-6182-25 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Orphenadrine citrate 60 mg/2mL Injection — NDC 0641-6182-25 (Billing 00641-6182-25)

by Hikma Pharmaceuticals USA Inc. · 25 BOX in 1 BOX / 10 VIAL in 1 BOX / 2 mL in 1 VIAL

This is a package of Orphenadrine citrate 60 mg/2mL Injection from Hikma Pharmaceuticals USA Inc., marketed since Apr 2003 and currently FDA-listed; retail pharmacies pay about $7.07 per mL (NADAC).

NDC 00641-6182-25
🏷️ FDA NDC (as labeled) 0641-6182-25 billing pads the labeler segment with a zero
This package
Contains2 mL in 1 vial Cost per mL$7.07 NADAC Per package$3,537.20 / 500 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $8.29/unit — full pricing hub ↓
Product page 00641-6182-10 Also comes in: 10 vials 0641-6182-10
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0641-6182-25 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0641 labeler · 6182 product · 25 package
Package marketed since
Apr 28, 2003
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0641618225 6
Medicaid fills, this package
6,557 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0641-6182-25
Product NDC 0641-6182
11-digit billing NDC 00641618225
NCPDP billing unit ML — per mL (volume)
RxCUI 994541
UNII X0A40N8I4S
Application # ANDA040463
SPL Set ID ed406e8a-ec00-4711-ae2b-3c5af4f15438
Established class (EPC) Muscle Relaxant
Physiologic effect Centrally-mediated Muscle Relaxation
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2003-04-28
Route INTRAMUSCULAR, INTRAVENOUS
Dosage form INJECTION
Substance ORPHENADRINE CITRATE
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 75100080102005
GPI class Orphenadrine Citrate
GCN Seq No 004593
GCN 17653
HICL code 001906
Ingredient (HICL) Orphenadrine Citrate
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.10.00
AHFS class Indirect-Acting Skeletal Muscle Relaxant
FDB label name ORPHENADRINE 60 MG/2 ML VIAL
FDB brand name Orphenadrine Citrate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 004593
  • GCN: 17653
  • GPI-14 (Medi-Span): 75100080102005
  • HICL (First Databank): 001906
  • AHFS class code: 12:20.10.00
  • RxCUI (RxNorm): 994541
Why two NDCs? The FDA registers this code as 0641-6182-25 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00641-6182-25. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Muscle Relaxant class.

Pharmacologic class Muscle Relaxant
Drug family (ATC) Ethers chemically close to antihistamines, Ethers, chemically close to antihistamines
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ORPHENADRINE 60 MG/2 ML VIAL Ingredient Orphenadrine Citrate
📗 Our plain-language guide HelloPharmacist
  • It's a common assumption, but orphenadrine actually doesn't directly relax tense muscles. Researchers believe its benefit comes from pain-relieving properties — so it helps you fee...
  • What exactly does orphenadrine do — does it just relax my muscles?
  • Take one extended-release tablet in the morning and one in the evening — that's twice a day. Try to stick to the same times each day. If you're unsure whether to take it with food...
  • How should I take the extended-release tablet?
📖 Read our full Orphenadrine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $7.074 $3,537.20 / 500 ml
Medicaid paysCMS SDUD · 12 mo $8.29 $4,143.60 / 500 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J2360 $7.777 / J2360 unit —
NADAC price history (per mL) — tap or hover for the price & month
Feb 2026 Mar 2026 May 2026 Jul 2026 $7.074 $7.074
Flat over the last 6 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0641-6182-25
11-digit billing NDC00641-6182-25
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ2360
DescriptorINJECTION, ORPHENADRINE CITRATE, UP TO 60 MG
Billing units / pkg0.5 units
How the units are derivedThis package is 2 ML; the HCPCS unit is 60 MG, so one package = 0.5 billing units.
Medicare Part B spend (2026 (Q1))$6,149 · 916 claims · $6.71 per claim (all NDCs under J2360)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00641-6182-10 0641-6182-10 Main listing 10 VIAL in 1 BOX / 2 mL in 1 VIAL $5.73 / mL $114.61 2003-04-28 — Active
00641-6182-25 You're viewing this 25 BOX in 1 BOX / 10 VIAL in 1 BOX / 2 mL in 1 VIAL $7.07 / mL $3,537.20 2003-04-28 — Active

Per mL, this pack runs about 23% above the cheapest pack (NDC 00641-6182-10, $5.73 vs $7.07 NADAC).

This pack accounts for about 37% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 25 box in 1 box / 10 vial in 1 box / 2 ml in 1 vial.
What NDC number is used to bill for this package of Orphenadrine citrate 60 mg/2mL Injection?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Orphenadrine Citrate 30 mg/mL 25021-0651-02 Sagent 10 vials $5.730 AP Availability likely save 19%
Orphenadrine citrate 60 mg/2mLthis 00641-6182-25 Hikma 10 vials $7.074 AP Availability likely —
Orphenadrine Citrate 30 mg/mL 00591-3222-47 Actavis 10 ampules — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2003
On the market since
Apr 2003
📍
2026
Currently FDA-listed
23 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Orphenadrine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 5.8 mg / 2 mL UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • 2 mg / 2 mL UNII 4VON5FNS3C
    Sodium metabisulfite is a preservative derived from sulfur compounds. It prevents microbial growth and oxidation in medicines, helping extend shelf life and maintain product stability.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerHikma Pharmaceuticals USA Inc.
Application holderHIKMA PHARMACEUTICALS USA INC
FDA applicationANDA040463 (ANDA)
Labeler code00641
First marketedApr 2003
Product typeHuman Prescription Drug
Portfolio727 products on file

More NDCs from Hikma Pharmaceuticals USA Inc. labeler code 00641

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 🔒 Drug Abuse and Dependence 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 28 words ▾

INDICATIONS AND USAGE Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

⏱️ Dosage and Administration 48 words ▾

DOSAGE AND ADMINISTRATION Adults - One 2 mL vial (60 mg) intravenously or intramuscularly; may be repeated every 12 hours. Relief may be maintained by one (100 mg) orphenadrine citrate tablet twice daily. Parenteral drug products should be inspected visually for particulate matter, whenever solution and container permit.

⛔ Contraindications 38 words ▾

CONTRAINDICATIONS Contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (megaesophagus) and myasthenia gravis. Contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

⚠️ Warnings 96 words ▾

WARNINGS Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine citrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly. Orphenadrine citrate injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.

The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than nonasthmatic people.

🤒 Adverse Reactions 140 words ▾

ADVERSE REACTIONS Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses.

Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported.

No causal relationship has been established. Rare instances of anaphylactic reaction have been reported associated with the intramuscular injection of orphenadrine citrate.

🤰 Pregnancy 49 words ▾

Pregnancy Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed.

🧒 Pediatric Use 24 words ▾

Pediatric Use Safety and effectiveness in children have not been established; therefore, this drug is not recommended for use in the pediatric age group.

🆘 Overdosage 66 words ▾

OVERDOSAGE Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.

🧬 Clinical Pharmacology 36 words ▾

CLINICAL PHARMACOLOGY The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense muscles in man. Orphenadrine citrate also possesses anticholinergic actions.

📦 How Supplied / Storage and Handling 113 words ▾

HOW SUPPLIED Orphenadrine Citrate Injection, USP is supplied as follows: Cartons of 10 ( NDC 0641-6182-10 ) 2 mL vials, each vial containing 60 mg of orphenadrine citrate in aqueous solution. Cartons of 25 ( NDC 0641-6182-25 ) 2 mL vials, each vial containing 60 mg of orphenadrine citrate in aqueous solution. Storage Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Protect from light. Single dose vial. Discard unused portion.

To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 1-877-845-0689. Manufactured by: Hikma Pharmaceuticals USA Inc.

Berkeley Heights, NJ 07922 Revised May 2023 462-734-02

📋 Description 95 words ▾

DESCRIPTION Orphenadrine citrate is the citrate salt of orphenadrine (±)- N , N -dimethyl-2-[( o -methyl-α-phenylbenzyl)oxy]-ethylamine citrate (1:1). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol.

Each vial contains 60 mg of orphenadrine citrate in aqueous solution. Each vial also contains: sodium metabisulfite, 2 mg; sodium chloride, 5.8 mg; sodium hydroxide, to adjust pH; and water for injection, q.s. to 2 mL. The structural formula is: C 18 H 23 NO•C 6 H 8 O 7 MW 461.50 Structural Formula

⚠️ Precautions 162 words ▾

PRECAUTIONS Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases. Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, cardiac arrhythmias.

Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended. Pregnancy Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine.

It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed. Pediatric Use Safety and effectiveness in children have not been established; therefore, this drug is not recommended for use in the pediatric age group.

🔒 Drug Abuse and Dependence 24 words ▾

DRUG ABUSE AND DEPENDENCE Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine.

📄 Package Label / Principal Display Panel 103 words ▾

PRINCIPAL DISPLAY PANEL - CONTAINER NDC 0641- 6182 -01 Rx only Orphenadrine Citrate Injection, USP 60 mg per 2 mL (30 mg/mL) For IV or IM use Discard unused portion 2 mL Single Dose Vial vial

PRINCIPAL DISPLAY PANEL -SHELF PACK NDC 0641- 6182 -10 Rx only Orphenadrine Citrate Injection, USP 60 mg per 2 mL (30 mg/mL) For Intravenous or Intramuscular use 10 x 2 mL Single Dose Vials NDC 0641- 6182 -25 Rx only Orphenadrine Citrate Injection, USP 60 mg per 2 mL (30 mg/mL) For Intravenous or Intramuscular use 25 x 2 mL Single Dose Vials sp 25 pack label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
6.6K
Units reimbursed last 4 qtrs
13.4K
Gross reimbursed last 4 qtrs
$110.8K
Avg / prescription
$16.90
Avg / unit
$8.2872
Latest quarter Q1 2026
1.6KRx
Medicaid pays / mL
$8.2872
gross reimbursed
vs
NADAC / mL
$7.0744
acquisition cost
=
Spread
+$1.2128
+17% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
90% MCO
Fee-for-service · 624 Rx Managed care · 5,933 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: 62 units · 3.2 per 100k residents ID Montana: 27 units · 2.4 per 100k residents MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 24 units · 0.1 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 86 units · 2.0 per 100k residents OR Nevada: 118 units · 3.7 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 1,342 units · 41.8 per 100k residents IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 1,868 units · 15.9 per 100k residents OH Pennsylvania: 48 units · 0.4 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 78 units · 3.9 per 100k residents NE Missouri: 432 units · 7.0 per 100k residents MO Kentucky: 1,318 units · 29.1 per 100k residents KY West Virginia: 94 units · 5.3 per 100k residents WV Virginia: 196 units · 2.2 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 156 units · 2.1 per 100k residents AZ New Mexico: 549 units · 26.0 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 154 units · 2.2 per 100k residents TN North Carolina: 22 units · 0.2 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: 212 units · 5.2 per 100k residents OK Louisiana: 823 units · 18.0 per 100k residents LA Mississippi: 266 units · 9.0 per 100k residents MS Alabama: 530 units · 10.4 per 100k residents AL Georgia: 174 units · 1.6 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 612 units · 2.0 per 100k residents TX Florida: 2,578 units · 11.4 per 100k residents FL
Units reimbursed · per 100k residents
0.141.8
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Iowa 41.8 /100k
2 Kentucky 29.1 /100k
3 New Mexico 26.0 /100k
4 Louisiana 18.0 /100k
5 Ohio 15.9 /100k
6 Florida 11.4 /100k
7 Alabama 10.4 /100k
8 Mississippi 9.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
10 vials00641-6182-10 11,170 Rx · $177,351
10 vials this page00641-6182-25 6,557 Rx · $110,816
Drug total (last 4 qtrs): 17,727 Rx · 35,850 units · $288,167 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Orphenadrine Citrate — the program that covers self-administered drugs. 3 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Orphenadrine Citrate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$43.5K
Claims incl. refills
881
Beneficiaries
744
Spend / beneficiary
$58.44
Spend / claim
$49.36
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00641-6178-01 · Hikma 00641-6184-25 · Hikma →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.